Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129


RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.

Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.

Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.


Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Norris EJ, Zhang Q, Jones WD, DeStephanis D, Sutker AP, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.


Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.

Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.


Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.

Norris EJ, Jones WD, Surleac MD, Petrescu AJ, Destephanis D, Zhang Q, Hamadeh I, Kneisl JS, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol Rep. 2018 Jan 17;23:41-44. doi: 10.1016/j.gore.2018.01.005. eCollection 2018 Feb.


Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.


HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.


Whisker dependent responsiveness of C57BL/6J mice to different behavioral test paradigms.

Haridas S, Ganapathi R, Kumar M, Manda K.

Behav Brain Res. 2018 Jan 15;336:51-58. doi: 10.1016/j.bbr.2017.08.004. Epub 2017 Aug 16.


Later Life Changes in Hippocampal Neurogenesis and Behavioral Functions After Low-Dose Prenatal Irradiation at Early Organogenesis Stage.

Ganapathi R, Manda K.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):63-74. doi: 10.1016/j.ijrobp.2017.01.243. Epub 2017 Feb 7.


Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.


Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.


Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.

Norris EJ, DeStephanis D, Tunquist B, Usmani S, Ganapathi R, Ganapathi M.

Blood Cancer J. 2016 Oct 7;6(10):e480. doi: 10.1038/bcj.2016.92. No abstract available.


Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.

Miller KR, Patel JN, Ganapathi MK, Tait DL, Ganapathi RN.

Gynecol Oncol. 2016 Jun;141(3):608-615. doi: 10.1016/j.ygyno.2016.03.004. Epub 2016 Mar 21. Review.


Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.

Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vaziri SA, Ganapathi RN.

Int J Cancer. 2016 Feb 1;138(3):679-88. doi: 10.1002/ijc.29815. Epub 2015 Sep 10.


Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs.

Ganapathi RN, Ganapathi MK.

Urol Oncol. 2014 Jan;32(1):1-4. doi: 10.1016/j.urolonc.2013.08.027. No abstract available.


Mechanisms regulating resistance to inhibitors of topoisomerase II.

Ganapathi RN, Ganapathi MK.

Front Pharmacol. 2013 Aug 1;4:89. doi: 10.3389/fphar.2013.00089. eCollection 2013.


Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.

Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, Sercia L, Wood L, Ganapathi MK, Bukowski RM, Ganapathi R.

Front Oncol. 2012 May 28;2:51. doi: 10.3389/fonc.2012.00051. eCollection 2012.


Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM.

Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5.


Chromoblastomycosis in a case of borderline lepromatous leprosy with recurrent type II lepra reaction.

Apte G, Gedam JR, Poojary S, Nagpur NG, Pai VV, Ganapathi R.

Lepr Rev. 2011 Sep;82(3):310-5. No abstract available.


Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13. doi: 10.1073/pnas.1111840108. Epub 2011 Nov 8.


A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.

Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R.

Clin Cancer Res. 2011 Dec 15;17(24):7754-64. doi: 10.1158/1078-0432.CCR-11-1002. Epub 2011 Oct 5.


Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R.

Cancer. 2012 Apr 1;118(7):1946-54. doi: 10.1002/cncr.26491. Epub 2011 Aug 31.


Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma.

Bennett KL, Campbell R, Ganapathi S, Zhou M, Rini B, Ganapathi R, Neumann HP, Eng C.

Genes Chromosomes Cancer. 2011 Aug;50(8):654-61. doi: 10.1002/gcc.20887. Epub 2011 May 16.


Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Grozav AG, Willard BB, Kozuki T, Chikamori K, Micluta MA, Petrescu AJ, Kinter M, Ganapathi R, Ganapathi MK.

Proteomics. 2011 Mar;11(5):829-42. doi: 10.1002/pmic.201000194. Epub 2011 Jan 31.


CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R.

Anticancer Res. 2010 Dec;30(12):4791-8.


Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.

Aydin H, Chen L, Cheng L, Vaziri S, He H, Ganapathi R, Delahunt B, Magi-Galluzzi C, Zhou M.

Am J Surg Pathol. 2010 Nov;34(11):1608-21. doi: 10.1097/PAS.0b013e3181f2ee0b.


Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.

Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, Ganapathi R.

Drug Metab Dispos. 2010 Nov;38(11):1962-6. doi: 10.1124/dmd.110.033951. Epub 2010 Jul 29.


DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK.

Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. Review.


Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer.

Wang C, Michener CM, Belinson JL, Vaziri S, Ganapathi R, Sengupta S.

Mol Cancer Ther. 2010 Jun;9(6):1709-18. doi: 10.1158/1535-7163.MCT-09-1024. Epub 2010 Jun 1.


Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.

Vaziri SA, Kim J, Ganapathi MK, Ganapathi R.

Curr Oncol Rep. 2010 Mar;12(2):102-8. doi: 10.1007/s11912-010-0085-4. Review.


Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2009 Aug;29(8):2961-9.


Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.

Grozav AG, Chikamori K, Kozuki T, Grabowski DR, Bukowski RM, Willard B, Kinter M, Andersen AH, Ganapathi R, Ganapathi MK.

Nucleic Acids Res. 2009 Feb;37(2):382-92. doi: 10.1093/nar/gkn934. Epub 2008 Nov 29.


Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

George S, Dreicer R, Au JJ, Shen T, Rini BI, Roman S, Cooney MM, Mekhail T, Elson P, Wientjes GM, Ganapathi R, Bukowski RM.

Clin Genitourin Cancer. 2008 Sep;6(2):79-85. doi: 10.3816/CGC.2008.n.012.


von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.


Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.

Sengupta S, Michener CM, Escobar P, Belinson J, Ganapathi R.

Gynecol Oncol. 2008 May;109(2):226-33. doi: 10.1016/j.ygyno.2007.12.024. Epub 2008 Mar 6.


Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.

Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG, Vaziri SA, Wang J, Gudkov AV, Rybicki LR, Bukowski RM, Yen A, Tanimoto M, Ganapathi MK, Ganapathi R.

Leukemia. 2006 Oct;20(10):1809-18. Epub 2006 Aug 17.


Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.

Anticancer Res. 2006 May-Jun;26(3A):1869-76.


Phase 1 trial of Anvirzel in patients with refractory solid tumors.

Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM.

Invest New Drugs. 2006 Sep;24(5):423-7.


Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer.

Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM.

Ann Oncol. 2006 May;17(5):860-5. Epub 2006 Mar 8.


Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.


Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53. Epub 2005 Nov 15.


A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC.

Mol Cancer Ther. 2005 Jun;4(6):948-55.


Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction.

Grozav AG, Hutson TE, Zhou X, Bukowski RM, Ganapathi R, Xu Y.

J Pharm Biomed Anal. 2004 Sep 21;36(1):125-31.


Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.

Hutson TE, Ganapathi R, Elson P, Mekhail T, Olencki T, Budd GT, Bukowski RM.

Invest New Drugs. 2004 Aug;22(3):277-84.


Renal cell carcinoma (RCC) and telomerase activity: relationship to stage.

Mekhail TM, Kawanishi-Tabata R, Tubbs R, Novick A, Elson P, Ganapathi R, Ganapathi M, Bukowski R.

Urol Oncol. 2003 Nov-Dec;21(6):424-30.


c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.

Vaziri SA, Grabowski DR, Tabata M, Holmes KA, Sterk J, Takigawa N, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2003 Sep-Oct;23(5A):3657-61.


Apoptotic pathways of epothilone BMS 310705.

Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R.

Gynecol Oncol. 2003 Oct;91(1):173-8.


Tubulin interacting agents: novel taxanes and epothilones.

Agrawal NR, Ganapathi R, Mekhail T.

Curr Oncol Rep. 2003 Mar;5(2):89-98. Review.


Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.

Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, Bukowski RM, Hickson ID, Andersen AH, Ganapathi R, Ganapathi MK.

J Biol Chem. 2003 Apr 11;278(15):12696-702. Epub 2003 Feb 4.

Supplemental Content

Loading ...
Support Center